Standardisation of Costs
- First Online:
- 401 Downloads
The lack of a uniform costing methodology is often considered a weakness of economic evaluations that hinders the interpretation and comparison of studies. Standardisation is therefore an important topic within the methodology of economic evaluations and in national guidelines that formulate the formal requirements for studies to be considered when deciding on the reimbursement of new medical therapies. Recently, the Dutch Manual for Costing: Methods and Standard Costs for Economic Evaluations in Health Care (further referred to as ‘the manual’) has been published, in addition to the Dutch guidelines for pharmacoeconomic research. The objectives of this article are to describe the main content of the manual and to discuss some key issues of the manual in relation to the standardisation of costs.
The manual introduces a six-step procedure for costing. These steps concern: (i) the scope of the study; (ii) the choice of cost categories; (iii) the identification of units; (iv) the measurement of resource use; (v) the monetary valuation of units; and (vi) the calculation of unit costs. Each step consists of a number of choices and these together define the approach taken. In addition to a description of the costing process, five key issues regarding the standardisation of costs are distinguished. These are the use of basic principles, methods for measurement and valuation, standard costs (average prices of healthcare services), standard values (values that can be used within unit cost calculations), and the reporting of outcomes. The use of the basic principles, standard values and minimal requirements for reporting outcomes, as defined in the manual, are obligatory in studies that support submissions to acquire reimbursement for new pharmaceuticals. Whether to use standard costs, and the choice of a particular method to measure or value costs, is left mainly to the investigator, depending on the specific study setting.
In conclusion, several instruments are available to increase standardisation in costing methodology among studies. These instruments have to be used in such a way that a balance is found between standardisation and the specific setting in which a study is performed. The way in which the Dutch manual tries to reach this balance can serve as an illustration for other countries.
- 6.Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York (NY): Oxford University Press, 1997Google Scholar
- 7.Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. 1st ed. New York (NY): Oxford University Press, 1996Google Scholar
- 12.Commonwealth Department of Health, Housing, Local Government and Community Services. Manual of resource items and their associated costs. Canberra: Commonwealth Department of Health, Housing, Local Government and Community Services, 1993Google Scholar
- 13.Baladi JF. A guidance document for the costing process. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1996Google Scholar
- 14.Oostenbrink JB, Koopmanschap MA, Rutten FFH. Manual for costing: methods and standard costs for economic evaluations in health care [in Dutch]. Amstelveen: College voor zorgverzekeringen, 2000Google Scholar
- 15.Riteco JA, de Heij LJM, van Luijn JCF, et al. Dutch guidelines for pharmacoeconomic research. Amstelveen: College Voor Zorgverzekeringen, 1999Google Scholar
- 18.Horngren CT. Cost accounting. 5th ed. Englewood Cliffs (NJ): Prentice-Hall, 1982Google Scholar
- 19.Dutch Ministry of Finance. Textbook financial governmental information and administration. The Hague: Dutch Ministry of Finance, 1995Google Scholar
- 20.Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997Google Scholar
- 21.Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee. Canberra: Commonwealth Department of Human Services and Health, 1995Google Scholar
- 26.Commissie Modernisering Curatieve Zorg. Gedeelde Zorg: Betere Zorg; Achtergrondstudies Van de Commissie Modernisering Curatieve Zorg. Roosendaal: Ammerlaan Pre-Press, 1994Google Scholar
- 27.Groeneveld JF. Specialistenhonoraria. Medisch Contact 1996; 27: 919–21Google Scholar